{'fraction_non_alphanumeric': 0.021453287197231833, 'fraction_numerical': 0.01453287197231834, 'mean_word_length': 4.626459143968872, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Contributions of the newly revised 2018 international federation of gynecology and obstetrics staging of cervical cancer

Introduction. According to the latest data from International Agency for
 Research on Cancer from 2018, global burden of cancer cervical cancer is the
 fourth most common cancer in women worldwide. The aim of this article was to
 present the contributions of the new, revised 2018 International Federation
 of Gynecology and Obstetrics staging of carcinoma of the cervix uteri,
 allowing much more precise staging with the use of any imaging modalities
 and/or pathological findings to allocate the stage and provide more
 effective treatment. International Federation of Gynecology and Obstetrics
 staging system. The main changes in the new staging system were made in IB
 stage of the disease, which now includes 3 subgroups i.e. substages for
 every 2 cm increments in tumor size: stage IB1 (< 2 cm), stage IB2 disease
 (2 to < 4 cm), and stage IB3 (? 4 cm). This system also incorporates the
 lymph node status into stage III cervical cancer, allowing imaging and/or
 pathological findings of lymph nodes to the pelvic and/or para-aortic nodes
 to assign stage IIIC disease. Conclusion. The main goal of the new staging
 system revision was to improve the accuracy of staging in order to provide
 more refined understanding of prognostic groups and facilitate better
 treatment for women with invasive cervical cancer.